Clene Sees Path Forward For ALS Candidate Despite Late-Stage Trial Failure
Touts Survival Signal
The US firm’s nanoparticle candidate has disappointed in a late-stage ALS trial but experts say secondary survival data could prove a silver lining given an increasingly flexible US regulatory environment.
You may also be interested in...
As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.